Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Heterogeneity of Tertiary Lymphoid Structures Predicts Distinct Malignancy and Immune Microenvironment in Prostate Cancer: a Retrospective Cohort Study
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT06484127
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China
Not Applicable
Completed
- Conditions
- Financial ToxicityBreast Neoplasm FemaleFinancial Navigation
- Interventions
- Behavioral: Financial NavigationOther: Usual Care
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 82
- Registration Number
- NCT06484140
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
Phase 2
Recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 87
- Registration Number
- NCT06475326
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 42
- Registration Number
- NCT06475287
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Advanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 32
- Registration Number
- NCT06470672
- Locations
- 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China
Enhanced vs. Routine Follow-Up After Total Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial
Not Applicable
Not yet recruiting
- Conditions
- Gastric CancerTotal GastrectomyFollow-upPostoperative CareQuality of Life
- Interventions
- Other: Enhanced Follow-up
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 158
- Registration Number
- NCT06468969
Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer
Phase 2
Recruiting
- Conditions
- Early Low Rectal Cancer
- Interventions
- Radiation: Short-course radiotherapyRadiation: Long-course radiotherapyDrug: PD-1 antibody (Toripalimab)
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 134
- Registration Number
- NCT06462053
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Multi-omics Model for Pancreatic Cancer Screening Using cfDNA
Recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- Diagnostic Test: A noninvasive cfDNA multi-omics assay
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 480
- Registration Number
- NCT06456281
- Locations
- 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China, Shanghai, Shanghai, China
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
Phase 2
Recruiting
- Conditions
- Rectal Cancer
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT06455124
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Cohort Study in Newly Diagnosed MZL
Recruiting
- Conditions
- Marginal Zone Lymphoma
- Interventions
- Other: patients receive optimal treatment or follow-up according to the characteristics of the disease
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 2500
- Registration Number
- NCT06449885
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath